https://www.lupus.org/news/first-person-receives-dose-of-drug-therapy-litifilimab-biib059-for-treatment-of-cutaneous
In the phase 2/3 AMETHYST trial, researchers aim to assess treatment effects on levels of skin disease activity.
first persondrug therapyreceivesdoselitifilimab